Sensei Biotherapeutics/$FTH
1D1W1MYTD1Y5YMAX
Capital at risk
About Sensei Biotherapeutics
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
- Ticker
- $FTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 29
- Headquarters
- Rockville, United States
- Website
- www.faeththerapeutics.com
FTH Metrics
BasicAdvanced
$908M
-
-$82.46
-0.31
-
Price and volume
Market cap
$908M
Beta
-0.31
52-week high
$42.14
52-week low
$7.45
Average daily volume
303K
Financial strength
Current ratio
19.693
Quick ratio
19.461
Total debt to equity
0.003
Interest coverage (TTM)
-1,148.84%
Profitability
EBITDA (TTM)
-36.64
Management effectiveness
Return on assets (TTM)
-20.79%
Return on equity (TTM)
-195.26%
Valuation
Price to book
5.25
Price to tangible book (TTM)
5.25
Price to free cash flow (TTM)
-2.46
Free cash flow yield (TTM)
-40.65%
Free cash flow per share (TTM)
-14.28
Growth
Earnings per share change (TTM)
287.03%
3-year earnings per share growth (CAGR)
40.95%
Bulls say / Bears say
The FDA granted Fast Track designation to PIKTOR plus paclitaxel for biomarker-selected advanced or recurrent endometrial cancer, potentially improving regulatory engagement for the lead program. (Faeth Therapeutics)
Faeth reported that the Phase 2 FTH-PIK-201 endometrial-cancer study remains on track for topline results by year-end 2026, while its Phase 1b/2 breast-cancer study has dosed its first patient, providing multiple near-term clinical catalysts. (SEC)
The company reported $186.4 million in cash, cash equivalents, and marketable securities at June 30, 2026, and said its resources should fund operations through topline readouts from both ongoing PIKTOR studies. (SEC)
PIKTOR remains clinically unproven: the company describes prior supporting Phase 1b data as open-label, uncontrolled, and based on a limited number of evaluable patients, while pivotal Phase 2 efficacy remains pending. (SEC)
Faeth has no product revenue and reported a $186.2 million net loss for the six months ended June 30, 2026; management expects continued operating losses and negative operating cash flow. (SEC)
The company has authorized an at-the-market offering of up to $150 million of common stock, creating a meaningful potential dilution overhang in addition to shares issuable from remaining convertible preferred stock. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 13 Sept 2026.
Upcoming events
No upcoming events
FTH News
AllArticlesVideos
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Business Wire21 hours ago
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
Business Wire1 week ago
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.